Pancreatic Cancer Research

ResearcherAffiliated Hangzhou First People's Hospital, Westlake University, School of MedicineNo recent work listed

Yuqiang Shan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8397-6188; OpenAlex author ID A5061756117. Sources: OpenAlex.

Their work

Papers
3 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 1 paper

Papers 3

  1. Knockdown of EIF3H inhibits the development and progression of pancreatic cancer by regulating cell proliferation and apoptosis in vitro. Co-author DOI 10.14715/cmb/2021.67.4.9↗
  2. EIF3B promotes cancer progression in pancreatic cancer. First author DOI 10.1080/00365521.2020.1868566↗
  3. MEX3A knockdown inhibits the development of pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12935-020-1146-x↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Weiming Zhu · 1 shared paper, 2022 · strength 0.19
  2. Hanzhang Zhu · 1 shared paper, 2021 · strength 0.16
  3. Changku Jia · 1 shared paper, 2021 · strength 0.16
  4. Xu-Bao Liu · 1 shared paper, 2020 · strength 0.11
  5. Xing Wang · 1 shared paper, 2020 · strength 0.11
  6. Hao Zhang · 1 shared paper, 2020 · strength 0.11
  7. Nengwen Ke · 1 shared paper, 2020 · strength 0.11
  8. Chunlu Tan · 1 shared paper, 2020 · strength 0.11
  9. Qingquan Tan · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.